10-Q: Yubo International Biotech Reports Q2 2024 Results Amidst Operational Challenges

Yubo International Biotech's Q2 2024 results reveal a significant decrease in revenue and increased operating expenses, leading to a larger net loss compared to the same period last year.

Summary

• Yubo International Biotech reported a net loss of $598,348 for the three months ended June 30, 2024, compared to a net loss of $367,327 for the same period in 2023.
• The company's revenue decreased to $0 for the three months ended June 30, 2024, from $1,430 in the same period of 2023.
• Operating expenses increased to $470,436 for the three months ended June 30, 2024, from $368,161 in the same period of 2023.
• For the six months ended June 30, 2024, the net loss was $1,007,853, compared to $683,994 for the same period in 2023.
• Revenue for the six months ended June 30, 2024, was $3,488, a significant decrease from $153,880 in the same period of 2023.
• Operating expenses for the six months ended June 30, 2024, totaled $882,518, up from $740,849 in the same period of 2023.
• The company's cash balance was $7,700 as of June 30, 2024, with a negative working capital of $3,191,054.
• The company has a going concern warning due to recurring operating losses and negative working capital.

Sentiment

Score: 2

Explanation: The document presents a very negative outlook due to significant revenue decline, increased losses, low cash balance, negative working capital, and a going concern warning. The company's reliance on a small number of customers and the risks associated with its VIE structure further contribute to the negative sentiment.

Positives

• The company had a small amount of cash from investing activities due to the sale of equipment.
• The company received capital contributions to a subsidiary from non-controlling interests.

Negatives

• The company experienced a significant decrease in revenue, with no sales in Q2 2024.
• Operating expenses increased, contributing to a larger net loss.
• The company recorded a loss on obsolete inventory of $127,895.
• The company has a very low cash balance and a significant negative working capital.
• The company's financial statements include a going concern warning.
• The company is heavily reliant on a small number of customers for revenue.

Risks

• The company's VIE structure in China poses risks related to regulatory compliance and potential penalties.
• The company's contractual arrangements with its VIE have not been tested in a court of law.
• The company faces risks associated with regulatory approvals on offshore offerings, antimonopoly regulatory actions, and oversight on cybersecurity and data privacy.
• The company's ability to continue as a going concern is dependent on obtaining additional capital resources.
• The company's reliance on a small number of customers for revenue creates a concentration risk.
• The company's operations are subject to complex and evolving PRC laws and regulations.
• The company may be subject to cybersecurity reviews and data privacy regulations in China.
• The company's ability to pay dividends is dependent on receiving distributions from its subsidiaries and VIE, which are subject to PRC regulations.
• The company's ability to enforce civil liabilities against its officers and directors in China is uncertain.

Future Outlook

The company intends to continue working toward identifying and obtaining new sources of financing and intends to raise additional capital in the third and fourth quarters of 2024. However, there are no assurances that the company will be successful in obtaining additional financing in the future.

Management Comments

• Management plans to obtain capital from management and significant shareholders sufficient to meet its operating expenses.
• Management is seeking third-party equity and/or debt financing.

Industry Context

The company operates in the biotechnology sector, which is characterized by high research and development costs and regulatory hurdles. The company's focus on stem cell technology places it in a niche market with potential for growth but also significant risks.

Comparison to Industry Standards

• The company's financial performance is significantly below industry standards for biotech companies, particularly in terms of revenue generation and profitability.
• Many comparable biotech companies are focused on drug development and clinical trials, while Yubo's focus is on stem cell storage and related services, making direct comparisons difficult.
• The company's reliance on a small number of customers is not typical for established biotech companies, which usually have a more diversified customer base.
• The company's negative working capital and going concern warning are significant red flags compared to industry benchmarks.

Related Party Transactions

• The company has payables due to related parties, including Mr. Jun Wang, Mr. Yang Wang, Ms. Huang Li, and Mr. Jin Wei.
• Yubo Beijing executed an Entrustment Technical Service Agreement with Beijing Zhenhuikang Biotechnology Co. LTD, an entity controlled by Mr. Yulin Cao.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and the uncertainties surrounding its VIE structure.
• Employees may be impacted by potential cost-cutting measures or restructuring due to the company's financial difficulties.
• Customers may be affected by potential disruptions in the company's operations or product offerings.
• Suppliers and creditors face increased risks due to the company's financial instability and going concern warning.

Next Steps

• The company intends to obtain additional capital resources.
• The company intends to raise additional capital in the third and fourth quarters of 2024.
• The company will continue to work towards identifying and obtaining new sources of financing.

Key Dates

Keywords

biotech, financial results, stem cells, China operations, VIE structure, going concern, revenue decline, operating expenses, net loss, regulatory risks